SciClone Announces Product Promotion Agreement Renewal With Key Industry Parnter Sanofi in China

SciClone Announces Product Promotion Agreement Renewal With Key Industry 
Parnter Sanofi in China 
FOSTER CITY, CA -- (Marketwire) -- 01/30/13 --  SciClone
Pharmaceuticals, Inc. (NASDAQ: SCLN) today announced that it has
successfully negotiated renewals of its exclusive product promotion
agreement with Sanofi for the China market. 
Under the terms of the Sanofi agreement, SciClone, through its wholly
owned subsidiary, Novamed Pharmaceuticals (Shanghai) Co., Ltd.
("Novamed"), exclusively promotes four key products: the
anti-epileptic Depakine(R) (sodium valproate); the hypnotic
Stilnox(R) (zolpidem); the ACE inhibitor Tritace(R) (ramipril) and
Xatral(R) (alfuzosine HCl), an alpha-1 adrenergic blocker used to
treat benign prostatic hyperplasia or BPH. Depakine revenues rank
second among SciClone's revenue-generating products and during the
last three years under the promotional agreement, sales have
increased significantly on an annual compounded basis. As the set of
current agreements will expire between the end of 2012 and June 30,
2013, Sanofi and Novamed have decided to group the products and renew
their agreement till December 31, 2013, which may be further extended
should both parties find agreement under the terms of the contract
extension. 
"We believe that the renewal of this promotion agreement is a
meaningful accomplishment for SciClone, and we are pleased with the
outcome of the negotiations with Sanofi, our important and valued
industry partner," said Friedhelm Blobel, Ph.D., SciClone President
and Chief Executive Officer. "We look forward to continuing to deepen
the market penetration and expand the commercial success of these
high quality, therapeutically differentiated products in China. We
are confident that with well structured agreements that are
consistent with our financial goals, the product promotion business
can make a significant contribution to our ongoing profitability as
our company moves forward." 
About SciClone  
SciClone Pharmaceuticals is a US-based, China-focused specialty
pharmaceutical company with a product portfolio of therapies for
oncology, infectious diseases and cardiovascular, urological,
respiratory, and central nervous system disorders. SciClone's
ZADAXIN(R) (thymalfasin) is approved in over 30 countries and may be
used for the treatment of hepatitis B (HBV), hepatitis C (HCV) and
certain cancers, and as a vaccine adjuvant, according to the local
regulatory approvals. Besides ZADAXIN, SciClone markets about 14
mostly partnered products in China, including Depakine(R), the most
widely prescribed broad-spectrum anti-convulsant in China;
Tritace(R), an ACE inhibitor for the treatment of hypertension;
Stilnox(R), a leading hypnotic for the short-term treatment of
insomnia (marketed as Ambien(R) in the US); and Aggrastat(R), a
recently-launched interventional cardiology product. SciClone is also
pursuing the registration of several other therapeutic products in
China. SciClone is headquartered in Foster City, California. For
additional information, please visit www.sciclone.com. 
Forward-Looking Statements 
This press release contains forward-looking statements regarding
expected financial results and expectations. Readers are urged to
consider statements that include the words "may," "will," "would,"
"could," "should," "might," "believes," "estimates," "projects,"
"potential," "expects," "plans," "anticipates," "intends,"
"continues," "forecast," "designed," "goal," "unaudited,"
"approximately" or the negative of those words or other comparable
words to be uncertain and forward-looking. These statements are
subject to risks and uncertainties that are difficult to predict and
actual outcomes may differ materially. These include risks and
uncertainties relating to: changes in results that may occur in
completing the close of SciClone's consolidated financial statements
for fiscal year 2012 and completing the audit of SciClone's
consolidated financial statements for fiscal year 2012; the course,
cost and outcome of regulatory matters; the Company's ability to
execute on its goals in China and on its objectives for revenue in
fiscal 2013; the challenges presented by integrating an acquired
business into existing operations; the variability in earnings on a
GAAP basis that may result from non-cash charges related to the
NovaMed acquisition; the dependence on third-party license, promotion
or distribution agreements including the need to renew such
agreements; operating an international business; the clinical trial
process, including the regulatory approval and the process of
initiating trials at, and enrolling patients at, clinical sites; the
effect of changes in its practices and policies related to the
Company's compliance programs and SciClone's ability to attract and
retain key personnel. SciClone cannot predict the timing or outcome
of the SEC and DOJ investigations, or of the level of its efforts
required to cooperate with those investigations, however the Company
has incurred substantial expenses in connection with the
investigations and related litigation and expects to incur additional
expense and the investigations could result in fines and further
changes in its internal control or other remediation measures that
could adversely affect its business. Please also refer to other risks
and uncertainties described in SciClone's filings with the SEC. All
forward-looking statements are based on information currently
available to SciClone and SciClone assumes no obligation to update
any such forward-looking statements. 
Depakine, Stilnox, Tritace and Xatral are registered trademarks of
Sanofi and/or its affiliates. 
Aggrastat is a registered trademark of Medicure International Inc. in
the United States, and Iroko Cardio LLC in numerous other countries. 
SciClone, SciClone Pharmaceuticals, the SciClone Pharmaceuticals
design, the SciClone logo and ZADAXIN are registered trademarks of
SciClone Pharmaceuticals, Inc. in the United States and numerous
other countries. 
Corporate Contacts 
Gary Titus
Chief Financial Officer
650.358.3456
gtitus@sciclone.com 
Jane Green
Investors/Media
650.358.1447
jgreen@sciclone.com 
 
 
Press spacebar to pause and continue. Press esc to stop.